Exact Mass: 313.0215
Exact Mass Matches: 313.0215
Found 30 metabolites which its exact mass value is equals to given mass value 313.0215
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
6-(BROMOMETHYL)-4-(3-METHOXYPROPYL)-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
6-(BROMOMETHYL)-4-(3-METHOXYPROPYL)-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
[2-(3-BROMO-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
[2-(3-BROMO-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
tert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate
tert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate
2-(7-amino-4-methyl-2-oxo-6-sulfochromen-3-yl)acetic acid
2-(7-amino-4-methyl-2-oxo-6-sulfochromen-3-yl)acetic acid
3-(2,6-dichloro-phenyl)-5-isopropyl-isoxazole-4-carboxylic acid methyl ester
3-(2,6-dichloro-phenyl)-5-isopropyl-isoxazole-4-carboxylic acid methyl ester
tert-Butyl N-[2-(4-bromophenyl)-2-oxoethyl]carbamate
tert-Butyl N-[2-(4-bromophenyl)-2-oxoethyl]carbamate
5-(2-thienyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
5-(2-thienyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
3-THIOPHENECARBOXYLIC ACID, 2-[(2-CHLOROACETYL)AMINO]-4-(2-FURANYL)-, ETHYL ESTER
3-THIOPHENECARBOXYLIC ACID, 2-[(2-CHLOROACETYL)AMINO]-4-(2-FURANYL)-, ETHYL ESTER
2-[[(4-AMINOPHENYL)SULFONYL]AMINO]-4-THIAZOLEACETIC ACID
2-[[(4-AMINOPHENYL)SULFONYL]AMINO]-4-THIAZOLEACETIC ACID
7-Amino-3-(1,2,3-triazol-4-ylthio)methyl cephalosporanic acid
7-Amino-3-(1,2,3-triazol-4-ylthio)methyl cephalosporanic acid
2-(2,4-dichloro-6-methylphenoxy)-N-(2-furylmethyl)acetamide
2-(2,4-dichloro-6-methylphenoxy)-N-(2-furylmethyl)acetamide
2-[(4-Aminophenylsulfonyl)amino]thiazole-5-acetic acid
2-[(4-Aminophenylsulfonyl)amino]thiazole-5-acetic acid
Phosphatidyl-L-serine
Phosphatidyl-L-serine
A class of aminophospholipids in which a phosphatidyl group is esterified to the hydroxy group of serine.
KRA-533
KRA-533
KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells.